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Malgorzata Mikulska,1 Valerio Del Bono,1 Anna Maria Raiola,2 Barbara Bruno,2
Francesca Gualandi,2 Domenico Occhini,2 Carmen di Grazia,2 Francesco Frassoni,2
Andrea Bacigalupo,2 Claudio Viscoli1Blood stream infections (BSI) are a well-known cause of morbidity and mortality in hematopoietic stem cell
transplant (HSCT) patients. The aim of this study was to analyze etiology and microbial resistance of BSI in
patients undergoing allogeneic HSCT in a single center over a 4-year period (2004-2007). There were 168
episodes of BSI in 132 patients (median 10 days after HSCT) and 182 pathogens were isolated. Gram-positive
bacteria (GPB) accounted for 57% of 182 isolates. Gram-negative rods (GNR) for 37% and fungi for 6%. All
patients received routine fluoroquinolone prophylaxis. There was a significant decrease in GPB/GNR ratio
over time, from 2.4 in 2004 to 1 in 2007 (P5.043). Among GPB, staphylococci decreased from 37 of 68 (64%)
in 2004-2005 to 8 of 35 (23%) in 2006-2007 (P\.002). The Enterococcus faecalis/E. faecium ratio decreased
from 4.5 in 2004 to 0.33 in 2007 (P5.006), whereas the total number of enterococcal strains per year did not
change. The incidence of Escherichia coli among GNR increased from 3 of 15 (20%) in 2004 to 13 of 21 (62%)
in 2007 (P5 .003). Fluoroquinolone-resistance was common, both among GPB and GNR (81% and 74%, re-
spectively). Mortality rate at 7 days after BSI was 11% (19 of 168), reaching 39% for Pseudomonas aeruginosa
BSI (7 of 18). BSI remains a frequent and potentially life-threatening complication of allogeneic HSCT, the
causative organism influencing 7- and 30-day mortality rate. BSI etiology may change rapidly, requiring imple-
mentation of new empirical-therapy schemes.
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Blood stream infections (BSI) are a well-known
cause of morbidity and mortality in hematopoietic
stem cell transplant (HSCT) patients, because of pro-
longed neutropenia, mucosal damage, and extensive
use of venous central lines [1]. BSI incidence varies
from 22% to 55.8% in all HSCT recipients, and is par-
ticularly high during the preengraftment phase [2-5].University of Genoa, Division of Infectious Diseases, San
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6/j.bbmt.2008.10.024However, BSI may also occur late after HSCT, and
are related to factors such as graft-versus-host disease
(GVHD), indwelling central venous catheters, and re-
lapse of underlying hematologic disease [6-8].
Even thoughonly about 40%of the febrile episodes
during neutropenia can be defined as infection, appro-
priate empirical antibiotic therapy is mandatory in case
of fever in severely immunocompromised hosts. To
provide the best empirical coverage, knowledge of
both general trends in etiology and antibiotic suscepti-
bility is critical. Over the last 20 years, the global epide-
miology ofHSCT-related infections seemed to reverse
its trends. In fact, the ratio betweenGram-positive bac-
teria—the leading cause of bacteremia in neutropenic
patients in the 1980s and early 1990s [9-11]—and
Gram-negative bacteria in BSI in HSCT patients was
reported to be decreased in some centers [4,12]. More-
over, a significant increase inmultidrug resistant bacte-
ria, such as Gram-negative rods and vancomycin
resistant enterococci, was observed [13-16].47
48 Biol Blood Marrow Transplant 15:47-53, 2009M. Mikulska et al.The aim of this study was to describe epidemiol-
ogy, clinical characteristics, etiology, and outcome of
BSI in allogeneic HSCT recipients and to track
changes—if any—of the epidemiology as well as mi-
crobial resistance that occurred in the examined time
period in a major Italian HSCT center.MATERIALS AND METHODS
Data Collection
The study is a review of BSI in all patients who un-
derwent allogeneic HSCT at the HSCT Unit of San
Martino Hospital in Genoa, Italy, a clinical unit that
performs about 85 HSCTs per year. Computerized
database of prospectively collected data was searched
for all the episodes of BSI occurred between January
1, 2004 and December 31, 2007. Additionally, clinical
charts of the patients who developed BSI were re-
viewed. All the information concerning demographics,
underlying disease, transplant procedures, BSI epi-
sode, and survival was noted. All BSI that occurred af-
ter the beginning of the conditioning regimen were
evaluated. Day of infusion of HSCT was considered
day 0.Definitions
All blood cultures were obtained at clinical suspi-
cion of systemic infection, usually fever. BSI was
defined as isolation of a bacterial or fungal pathogen
from at least 1 blood culture. For coagulase negative
staphylococci (CoNS), corynebacteria, and other com-
mon skin contaminants, positive results from 2 consec-
utive blood cultures were required. BSI was considered
polymicrobial if 2 or more pathogens were isolated in
a single blood culture or in separate blood cultures
obtained 48 hours apart. Bacteremia occurring more
than 14 days after a previous episode and separated
by repeatedly negative blood cultures was considered
to be a separate BSI. Pathogens with intermediate sus-
ceptitibility or resistance were considered as resistant.
Gram-negative rods (GNR) were defined as ESBL
producers if resistant to aztreonam and third-
generation cephalosporins, whereas they were consid-
ered multidrug-resistant (MDR) if resistant to at least
2 of the following: ceftazidime, piperacillin/tazobac-
tam, or carbapenems. Neutropenia was defined as an
absolute neutrophil count below 0.5 109/L. Diagno-
sis and clinical grading of acute and chronic GVHD
(aGVHD, cGVHD) were performed according to
established criteria [17,18], and GVHD was consid-
ered a significant underlying condition only in case
of GVHD grade 2 or more, or chronic extensive
GVHD.Despite the fact that the study was not structured
to assess the attributable mortality, overall survival at
7 and 30 days after BSI was noted.
Transplantation Procedures andManagement of
Infections
Transplantation was performed according to insti-
tutional protocols, and the procedures were described
elsewhere [19]. Briefly, the most frequent myeloabla-
tive conditioning included either total-body irradia-
tion with 990 or 1200 cGy (related HLA-identical
donor or others, respectively) and cyclophosphamide
(Cy) 120 mg/kg in 2 days or a thiotepa-based regimen
(thiotepa 15 mg/kg and Cy 120-150 mg/kg). Reduced-
intensity conditioning (RIC) included lower dose thio-
tepa (10 mg/kg) or fludarabine combined with Cy.
Standard GVHD prophylaxis included cyclosporine
(CsA) and methotrexate (MTX). Cord blood recipi-
ents, instead of MTX, received mycophenoplate mo-
phetil (MMF) 15 mg/kg twice a day from day 1 to 28
after HSCT. Antithymocyte globulin (ATG) (Thymo-
globulin, Genzyme, Cambridge, MA), at dosages 6 to
15 mg/kg, was administered to recipients of HSCT
others than from related HLA-identical donor.
All patients were cared for in single rooms with
positive pressure and high-efficiency particulate air fil-
tration, and received antifungal prophylaxis with fluco-
nazole from the start of conditioning until day 80 after
HSCT. They received CMV prophylaxis with foscar-
net until day 100 after HSCT. Ciprofloxacin was used
as antibacterial prophylaxis from the start of condi-
tioning until neutrophil engraftment. From engraft-
ment until the end of immunosuppressive therapy
and immunologic recovery, prophylaxis against Pneu-
mocystis jiroveci and herpetic infections were provided,
with trimethoprim-sulfamethoxazole (960 mg twice
a day, 3 times a week) and acyclovir (400 mg/m2 twice
a day), respectively.
In case of fever (defined as pyrexia of 38C) or
other signs or symptoms of infection, prophylactic an-
tibiotics were stopped and patients were treated with
broad-spectrum intravenous antibiotics at the discre-
tion of the attending physicians. Usually, piperacil-
lin/tazobactam was started and an antistaphylococcal
agent (usually vancomycin) was added for fever persist-
ing more than 72 h. Antifungal agents, predominantly
lipid formulations of amphotericin B, were added in
case of persistent fever (.96 h) or suspected fungal in-
fection. Antibiotics were modified according to the
susceptibility of all organisms isolated.
Statistical Analysis
P values were calculated with chi-square or Fisher
tests. Two-sided Ps of .05 or less were considered sig-
nificant. All the statistical analyses were performed
with NCSS forWindows and SAS (NCSS 2006, Kays-
ville, UT).
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Patients’ Characteristics
During the 4-year observation period, BSI oc-
curred in 132 patients. Median age was 40 years (range:
13 – 64) and 81 (61%) were male. The most common
diagnosis was acute leukemia (n 5 78, 59%), followed
by other lymphoproliferative diseases (n 5 18, 14%)
such as non-Hodgkin lymphoma (n5 8), Hodgkin dis-
ease (n 5 5), multiple myeloma (n 5 4), and chronic
lymphatic leukemia (n 5 1). Other underlying condi-
tions includedmyelofibrosis or chronic myeloid leuke-
mia (n5 13, 10%), myelodysplastic syndrome (n5 12,
9%), acute aplastic anemia and paroxysmal nocturnal
hemoglobinuria (n 5 7), and other autoimmune dis-
eases (hemophagocytosis, systemic lupus erythemato-
sus, Behc¸et’s disease, 1 patient each). Fifty (38%)
patients were classified as phase 1 of underlying disease
(first complete remission or inactive disease after the
first line of treatment), 36 (27%) were in phase 2 (equal
to or greater than second complete remission or inac-
tive disease after more that first line of treatment),
whereas 46 (35%) had active disease at HSCT.
All the patients received allogeneic HSCT at our
institution, 49 (37%) from related HLA-identical do-
nor, 41 (31%) from matched unrelated, 19 (14%)
from mismatched related donor, 13 (10%) from cord
blood, and 10 (8%) frommismatched unrelated donor.
Of those who developed BSI, 120 were trans-
planted during the observation period and 12 received
HSCT before January 1, 2004.
Incidence and Timing of BSI
All BSI episodes observed during the study period
were included in the study, even if patients had actually
been transplanted earlier. The total number of patients
who developed at least 1 episode of BSI during the
study period was 132; 103 (78%) of them had a single
episode, 24 (18%) had 2 episodes, and 5 (4%) hadmore
than 2 episodes. The total number of BSI episodes was
168, with isolation of 182 pathogens. To obtain infor-
mation about the incidence of BSI, we calculated that
out of 343 patients who received HSCT during the
study period, 116 (34%) developed at least 1 episode
of BSI.
Median time of BSI was day110, ranging from28
to 4876. Seventeen (10%) episodes occurred before
HSCT, 101 (60%) within 30 days after HSCT and
50 (30%) more than 30 days after HSCT. Considering
solely those patients (n 5 108) who had sepsis after
HSCT, time to BSI was 12 days (range: 1-4876).
Etiology of BSI
Among 168 episodes, 91 (54.2%) were caused by
Gram-positive bacteria (GPB), 54 (32.1%) by GNR,
and 9 (5.4%) by fungi. In addition, there were 14(8.3%) polymicrobial BSI with 24 isolated pathogens:
12 GPB, 14 GNR, and 2 Candida.
Out of 182 pathogens isolated, 57% were GPB,
37% were GNR, and 6% were fungi (11 Candida spe-
cies). Detailed etiology is outlined in Table 1.
There was a significant change in the etiology of
BSI during the study period. As shown in Figure 1,
during the first 2 years GPB isolates were more fre-
quent than GNR; since 2006, this difference was no
longer present. Whereas the overall number of GNR
per year remained stable, GPB isolates decreased,
with a consequent relative percent GNR increase
from 28% in 2004 to 48% in 2007 (Figure 1). The
GPB/GNR ratio decreased significantly from 2.4 in
2004 to 1 in 2007 (P 5 .043); and from 2 in years
2004-2005 to 1 in years 2006-2007 (P 5 .029).
Among 103 GPB, the most frequent were Staphylo-
coccus species (44%), Enterococcus species (39%) and
Streptococcus viridans (11%). The number of isolated
staphylococci decreased sharply during the observa-
tion period, from 54% (37 of 68) in 2004-2005 to
23% (8 of 35) in 2006-2007 (P 5 .002). The number
of enterococcal isolates per year remained stable, but
Enterococcus faecium replaced Enterococcus faecalis as the
predominant species, with E. faecalis to E. faecium ratio
decreasing from 4.5 in 2004 to 0.3 in 2007, P 5 .006
(Figure 2).
Escherichia coli and Pseudomonas aeruginosa were the
most frequently isolated GNR (37% and 26% of
GNR, respectively). The prevalence of E. coli among
GNR increased, from 20% in 2004 (3 of 15) to 62%
in 2007 (12 of 21), P 5 .026.
Among 11 Candida BSI, Candida krusei was the
most frequent species (36%). Seven fungal BSI oc-
curred during neutropenia (4 before engraftment and
3 during secondary neutropenia), 3 during GVHD
and 1 episode of C. parapsilosis BSI was related to
indwelling central venous catheter.
Out of 168 BSI episodes, 129 (77%) occurred dur-
ing neutropenia, 21 (12%) during GVHD, and 18
(11%) under other conditions. Of 21 BSI that were
GVHD related, 14 (67%) were caused by GNR, 4
(19%) by GPD, and 3 (14%) by Candida. Detailed
etiology of single pathogen bacterial BSI during
neutropenia, GVHD and other periods is shown in
Figure 3.Antibiotic Resistance
All 41 CoNS and 3 of 4 Staphylococcus aureus iso-
lates were resistant to oxacillin. Moreover, 64% (7 of
11) of isolates of Streptococcus viridans isolates resulted
in resistant to penicillin. There was a major shift in
antimicrobial resistance among enterococci. Resis-
tance to ampicillin increased from 43% (7 of 20) in
2004-2005 to 70% (14 of 20) in 2006-2007, P 5 .027
(Figure 4).
Table 1. Etiology of 168 Blood Stream Infections with 182 Pathogens Isolated between 01/01/04 and 31/12/07 in 132 Allogeneic
Stem Cell Transplant Recipients
Organism
Number, (%)
2004 2005 2006 2007 Total, 182
Gram positive 36 (68%) 32 (58%) 14 (47%) 21 (48%) 103 (57%)
Staphylococcus 19 18 4 4 45
Coagulase negative 18 17 2 4 41
Staphylococcus aureus 1 1 2 0 4
Enterococcus 11 9 7 13 40
Enterococcus faecalis 9 6 3 3 21
Enterococcus faecium 2 2 4 9 17
Others 0 1* 0 1† 2
Viridans streptococci 4 4 2 1 11
Corynebacterium 2 1 0 2 5
Others 0 0 1‡ 1§ 2
Gram negative 15 (28%) 18 (33%) 14 (47%) 21 (48%) 68 (37%)
Escherichia coli 3 5 4 13 25
Pseudomonas aeruginosa 6 3 4 5 18
Klebsiella pneumoniae 2 0 3 2 7
Enterobacter 2 4 0 1 7
Stenotrophomonas maltophilia 1 2 2 0 5
Burkholderia cepacia 0 2 1 0 3
Others 1¶ 2^ 0 0 3
Candida 2 (4%) 5 (9%) 2 (7%) 2 (5%) 11 (6%)
krusei 2 1 1 0 4
albicans 0 2 0 0 2
parapsilosis 0 0 1 1 2
species 0 2 0 0 2
glabrata 0 0 0 1 1
*Enterococcus species.
†Enterococcus avium.
‡Rothia mucillaginosa.
§Streptococcus pneumoniae.
¶Pseudomonas species.
^Pseudomonas species and Acinetobacter species.
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(50%) were resistant to third- generation cefalosporin
(namely, ceftazidime), 3 (16%) were resistant to piper-
acillin/tazobactam, and 8 (44%) to carbapenems; 2
strains were resistant to all antimicrobials except for
colistin. Among others, GNR rods, 18% (7 of 25) of0%
20%
40%
60%
80%
100%
2004 2005 2006 2007
Gram + Gram -
Figure 1. Percentage of Gram-positive and Gram-negative bacteria
isolated from blood stream infections over the 4-year period. The
Gram-positive to Gram-negative bacteria ratio decreased significantly:
from 2.4 in 2004 to 1 in 2007, P 5 .043; and from 2 in years 2004-
2005 to 1 in 2006-2007, P 5 .029.E. coli, 86% (6/7) of K. pneumoniae, and 57% (4 of 7)
of Enterobacter species were ESBL producers. E. coli
was resistant to ceftazidime in 28%, to piperacillin/ta-
zobactam in 24%, and no resistant strains to carbape-
nems were found. The rate of ESBL-producing
bacteria remained stable during each year of the study,0%
20%
40%
60%
80%
100%
2004 2005 2006 2007
E. faecalis E. faecium Others
Figure 2. Etiology change among Enterococcus species throughout the
study period, percent values of number of isolates. The number of iso-
lates remained stable, but E. faecium replaced E. faecalis as the predom-
inant species with E. faecalis to E. faecium ratio decreasing from 4.5 in
2004 to 0.3 in 2007, P 5 .006.
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Figure 3. Different etiology of single bacterial blood stream infections
(BSI) during neutropenia (129 BSI), graft-versus-host-disease (GVHD)
(21 BSI) and other periods (18 BSI). Note: Neutropenia: staphylococci
25%, Enterococci 28%, otherGram-positive 14%, E.coli 14%, P. aeruginosa
9%, other Gram-negative 10%; GVHD: 11%, 11%, 0%, 17%, 33%, 28%;
other periods: 56%, 13%, 13%, 6%, 6%, 6%, respectively.
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(5 of 16) during each year of the study. Overall preva-
lence of ESBL producing E. coli, K. pneumoniae, and
Enterobacter was 44% (17 of 39). Even though GNR
BSI rate increased significantly in our center, the inci-
dence of MDR remained stable. Detailed antimicro-
bial sensitivity of GNR is presented in Table 2.
Fluoroquinolone (FQ) resistance was frequent,
with only 19%ofGPB and 26%ofGNRbeing suscep-
tible to FQ (no data for 4 isolates of Streptococcus viri-
dans). Among GNR, resistance to fluoroquinolones
increased during the 4 years of the study, although
the difference was not statistically significant (60%,
72%, 71%, and 86%. respectively).0%
20%
40%
60%
80%
100%
2004 2005 2006 2007
Ampi-S, vanco-S Ampi-R, vanco-S Ampi-R, vanco-R
Figure 4. Resistance changes among Enteroccoccus species throughout
the study period; percent values of number of isolates. Ampicillin-
susceptible (Ampi-S) isolates decreased in 2006-2007 compared to
2004-2005, P 5 .027. Ampicillin and vancomycin resistant (Ampi-R,
vanco-R) strains remained stable.Outcome
The crudemortality rate at 7 and 30 days after each
BSI episode was 11.3% (19 of 168) and 20.2% (34 of
168), respectively. Analyzing mortality according to
BSI etiology, 7-day mortality rate was 7% (6 of 91)
in case of single GPB BSI, 17% (9 of 54) for single
GNR BSI, 22% (2 of 9) for Candida BSI, and 14%
for polymicrobial BSI (2 of 14); 30-day mortality rate
was 18% (16 of 91), 24% (13 of 54), 22% (2 of 9),
and 21% (3 of 14), respectively. Pseudomonas aeruginosa
(7 of 18, 39%) was the pathogen with the highest asso-
ciated 7-day mortality rate, followed by Candida (2 of
9, 22%), Klebsiella pneumoniae (1 of 6, 17%), and poly-
microbial infection (2 of 14, 14%) (P 5 .011). Results
of mortality rates at 7 and 30 days after BSI are shown in
Table 3.DISCUSSION
This study reports a 34% rate of BSI occurring in
HSCT recipients, either before or after BMT proce-
dure. We observed—as is already shown in other cen-
ters—a high incidence of BSI in allogeneic HSCT,
particularly during the preengraftment phase. How-
ever, we also showed that a consistent number of BSI
occurred late after HSCT, concomitantly with clinical
conditions such as secondary (recurrent) neutropenia
and/or GVHD.
In our center, BSI etiology changed, with a signifi-
cant decrease of the Gram-positive/Gram-negative
bacteria ratio, in line with recent reports analyzing
similar patient populations [4,12,20]. This shift oc-
curred progressively during the 4 years of the study,
appearing, therefore, as a real change in microbial
ecology and not only an incidental and transitory phe-
nomenon. In addition, when comparing our study with
a previous one carried out in our center [19], the num-
ber of GNR as BSI agents increased from 27 in years
1998-2002 to 68 in years 2004-2007.
The high proportion of CoNS during the first 2
years of our study is unlikely to be expression of con-
tamination rather than true bacteremia, because rigor-
ous definition criteria of BSI were applied throughout
the study, in accordance with other investigators
[2,6,21]. The sharp decrease of CoNS BSI in the last
2 years of our observation is difficult to explain. In
HSCT patients, the sources of most BSI are usually
the skin, the oral mucosa, or the gastrointestinal (GI)
tract. Although the aim of the current study was not
finding the BSI source, it is likely that the oral mucosa
or the GI tract replaced the skin as a portal of entry,
given the parallel increase of E. coli and other GNR.
Further prospective studies are warranted to better in-
vestigate the reasons for this shift.
The development of resistance to antimicrobial
agents remains an important concern in the
Table 2. Antibiotic Susceptibility in 68 Gram-Negative Isolates Responsible for 66 Episodes of Blood Stream Infections
Organism (Number)
Number (%)
FQ—R
Third-Generation
Cephalosporin—R Pip/taz—R Carbapenem—R ESBL Producers MDR
Total (68) 50 (74%) 30 (44%) 18 (26%) 17 (25%) 17 (44%) 24 (35%)
Escherichia coli (25) 23 (92%) 7 (28%) 6 (24%) 0 7 (28%) 3 (12%)
Pseudomonas aeruginosa (18) 13 (72%) 9 (50%) 3 (16%) 8 (44%) — 10 (55%)
Klebsiella pneumoniae (7) 6 (86%) 6 (86%) 4 (57%) 1 (14%) 6 (86%) 5 (71%)
Enterobacter (7) 5 (71%) 4 (57%) 1 (14%) 1 (14%) 4 (57%) 1 (14%)
Stenotrophomonas maltophilia (5) 4 (80%) 5 (100%) 5 (100%) 5 (100%) — 5 (100%)
Burkholderia cepacia (3) 0 0 0 3 (100%) — 1 (33%)
Others* (3) 0 0 0 0 — 0
ESBL indicates extended spectrum beta-lactamase; FQ, fluoroquinolone; MDR, multidrug resistant; Pip/taz, piperacillin-tazobactam; R, resistant.
*Two Pseudomonas species; 1 Acinetobacter species.
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MDR infections are known to be associated with in-
creased mortality and costs [22,23]. In fact, GNR bac-
teremia has always been considered an ominous sign,
because of its high mortality rate. Furthermore,
GNR antimicrobial resistance could hamper an effec-
tive empirical treatment.We found anMDR incidence
of 35%, for the whole GNR population as well as for
individual pathogens, such as P. aeruginosa, E. coli,
and K. pneumoniae. This MDR incidence was higher
than that found in an European study focused on
GNR bacteremia [24], possibly because of the peculiar
clinical characteristics of the study patients, repeatedly
and heavily treated with broad-spectrum antibiotics in
other centers before being admitted in our unit. How-
ever, the increase of MDR GNR as a cause of BSI is
very worrisome, because of the lack of new agents
active on GNR, particularly Pseudomonas.
Considering the widespread FQ prophylaxis, it is
not surprising that FQ resistance was frequent, with
less than one-fifth of GPB and one-third of GNR
being susceptible to FQ. Therefore, given the high
incidence of FQ-resistance in our patients, the imple-
mentation of prophylactic protocols should be care-
fully evaluated.Table 3. Seven- and 30-Day Crude Mortality Rate Divided by
Bacterial Strain in 168 Episodes of Blood Stream Infection in Re-
cipients of allogeneic Hematopoietic Stem Cell Transplant
Bacterial Strain,
Number of Patients
7-Day Mortality,
Number (%)
30-Day Mortality,
Number (%)
Total
Staphylococci, 39 2 (5) 4 (10)
Enterococci, 35 4 (11) 8 (23)
Streptococcus viridans, 7 0 (0) 3 (43)
Other Gram-positive
bacteria, 10
0 (0) 1 (10)*
Pseudomonas aeruginosa, 18 7 (39) 8 (44)
Escherichia coli, 20 0 (0) 1 (5)
Klebsiella pneumoniae, 6 1 (17) 1 (14)
Other Gram-negative
bacteria, 12
1 (8) 3 (25)†
Candida, 9 2 (22) 2 (22)
Polymicrobial, 14 2 (14) 3 (21)
*Corynebacterium species.
†Two Burkholderia cepacia, 1 Stenotrophomonas maltophilia.Enterococci remained an important threat in our
patients, with constantly high prevalence of these bac-
teria since 1998 [19]. However, a major shift in species,
and consequently in antimicrobial resistance, was ob-
served from 2004 to 2007. E. faecium, constantly resis-
tant to ampicillin and in 24% of isolates resistant to
vancomycin (VRE), replaced E. faecalis as the most fre-
quent species. The empirical use of vancomycin is con-
troversial, and probably not indicated.Nevertheless, in
our center it remains common practice. For the time
being, the incidence of VRE bacteremia remained sta-
ble but as suggested by other reports, its incidence will
probably rise [13,15,16].
Although the study was not designed to assess the
mortality attributable to BSI, some comments on
short-term survival can be made. The 7-day mortality
in the whole cohort was as high as 11%, with different
rates depending on the causal pathogen. In fact , similarly
to results of other studies [3,4,25], P. aeruginosa andCan-
dida were associated to the highest mortality rate. Even
though mortality rate was the lowest in case of Gram-
positive BSI, it still reached 7%.Considering that, unlike
in other studies [3], viridans Streptococci accounted for
very low mortality rate, overall Gram-positive fatality
rate is because of enterococci and staphylococci.
However, despite important changes in BSI etiology
and antimicrobial resistance, the 30-day mortality did
not increase when compared to the 1998-2001 study
(20% and 26%, respectively), probably because the 30-
day mortality is a variable depending more on the
underlying disease than the infectious event.
There are some limitations to this study. As with
many other studies, the current 1 is retrospective in na-
ture. In a population of allogeneic HSCT recipient,
the attributable mortality is often difficult to establish.
In fact, several coexisting patoneologies (GVHD, re-
lapse, infection, bleeding disorders), may be not only
the direct cause of death but also may reciprocally
overlap. Therefore, we chose to analyze only short-
term survival after BSI, although some pathogens
may not be responsible for the high post-BSI mortal-
ity, and the sepsis per se might be a sign of poor clinical
conditions [13].
Biol Blood Marrow Transplant 15:47-53, 2009 53Blood Stream Infections in Allogeneic HSCT RecipientsIn summary, BSI is a frequent and potentially life-
threatening complication of HSCT.
The type of causative organism influenced mortal-
ity early after BSI. BSI etiologymay change rapidly, re-
quiring implementation of new empirical-therapy
schemes. Therefore, regularly performed epidemio-
logic surveillance is mandatory.ACKNOWLEDGMENTS
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